Baidu
map

Circulation:早绝经是克隆性造血和冠脉疾病的独立风险因素!

2021-02-02 MedSci原创 MedSci原创

早绝经,女性心血管疾病和克隆性造血风险增加!

早绝经是女性血管疾病的独立危险因素,但这种关联的潜在机制尚不清楚。不确定潜能的克隆性造血(CHIP)是一种年龄相关的具有致白血病突变但未发现恶性肿瘤的造血细胞扩增,与动脉粥样硬化加速相关。早绝经是否与CHIP相关尚不明确。

研究人员从UK生物库中筛选了11495位40-70岁的、从女性健康倡议数据库中筛选了8111位50-79岁的有全外显子测序的绝经妇女。早绝经被定义为40岁前自然或手术绝经。共主要结果是存在任何变异等位基因频率>0.1的CHIP。经年龄、种族、祖先的前10个主要成分、吸烟、糖尿病和激素治疗使用等因素调整后,用Logistic回归检验早绝经与CHIP的相关性。次要分析纳入自然 vs 手术早绝经和基因特异性CHIP亚型。

绝经后女性CHIP的发生率

本研究共纳入19606位女性,包括418位(2.1%)自然早绝经的女性和887位(4.5%)手术早绝经的女性。在队列间,有 vs 无早绝经史的绝经后女性CHIP的发生率分别为8.8% vs 5.5%(p<0.001)

早绝经与CHIP相关性

经多变量校正后,早绝经与CHIP独立相关(所有CHIP:优势比 1.36[95%CI 1.10-1.68];P=0.004; 等位基因频率>0.1的CHIP:优势比 1.40[95%CI 1.30-2.80];P<0.001),但在手术早绝经的女性中的差异很小或无显著性。

有无CHIP女性的冠脉疾病发生率

在基因特异性分析中,只有DNMT3A CHIP与早绝经明显独立相关。在绝经的中龄女性中,CHIP与偶发冠状动脉疾病独立相关(与所有CHIP相关的风险比:1.36[95%CI 1.07-1.73];P=0.012;与等位基因频率>0.1的CHIP相关的风险比 1.48[95%CI 1.13-1.94];P=0.005)。

综上,早绝经,特别是自然早绝经,与绝经后女性中的CHIP独立相关。自然早绝经可能是易患CHIP和CHIP相关心血管疾病的危险信号。

原始出处:

Michael C. Honigberg, et al. Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. Circulation. 2021;143:410–423

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660241, encodeId=33e61660241cd, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Fri Dec 17 22:03:07 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257261, encodeId=8d7e125e261e9, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490495, encodeId=733d1490495ac, content=<a href='/topic/show?id=37ab2891e94' target=_blank style='color:#2F92EE;'>#克隆性造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28917, encryptionId=37ab2891e94, topicName=克隆性造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b048776512, createdName=jinweidong, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494768, encodeId=89561494e68d2, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572988, encodeId=f7ff15e2988bd, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-12-17 aids221
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660241, encodeId=33e61660241cd, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Fri Dec 17 22:03:07 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257261, encodeId=8d7e125e261e9, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490495, encodeId=733d1490495ac, content=<a href='/topic/show?id=37ab2891e94' target=_blank style='color:#2F92EE;'>#克隆性造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28917, encryptionId=37ab2891e94, topicName=克隆性造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b048776512, createdName=jinweidong, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494768, encodeId=89561494e68d2, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572988, encodeId=f7ff15e2988bd, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660241, encodeId=33e61660241cd, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Fri Dec 17 22:03:07 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257261, encodeId=8d7e125e261e9, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490495, encodeId=733d1490495ac, content=<a href='/topic/show?id=37ab2891e94' target=_blank style='color:#2F92EE;'>#克隆性造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28917, encryptionId=37ab2891e94, topicName=克隆性造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b048776512, createdName=jinweidong, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494768, encodeId=89561494e68d2, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572988, encodeId=f7ff15e2988bd, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660241, encodeId=33e61660241cd, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Fri Dec 17 22:03:07 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257261, encodeId=8d7e125e261e9, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490495, encodeId=733d1490495ac, content=<a href='/topic/show?id=37ab2891e94' target=_blank style='color:#2F92EE;'>#克隆性造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28917, encryptionId=37ab2891e94, topicName=克隆性造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b048776512, createdName=jinweidong, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494768, encodeId=89561494e68d2, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572988, encodeId=f7ff15e2988bd, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-04 俅侠
  5. [GetPortalCommentsPageByObjectIdResponse(id=1660241, encodeId=33e61660241cd, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Fri Dec 17 22:03:07 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257261, encodeId=8d7e125e261e9, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490495, encodeId=733d1490495ac, content=<a href='/topic/show?id=37ab2891e94' target=_blank style='color:#2F92EE;'>#克隆性造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28917, encryptionId=37ab2891e94, topicName=克隆性造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b048776512, createdName=jinweidong, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494768, encodeId=89561494e68d2, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572988, encodeId=f7ff15e2988bd, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Thu Feb 04 12:03:07 CST 2021, time=2021-02-04, status=1, ipAttribution=)]

相关资讯

JACC:铂铬合金依维莫司洗脱支架用于冠脉疾病的长期安全性和疗效

经过5年的随访,PtCr-EES显示出与CoCr-EES相当的安全性和疗效,支架血栓形成率及其他不良事件发生率低。

Circulation:生物可吸收支架的3年结局:来自ABSORB随机试验的个体患者数据Meta分析

与合金依维莫司洗脱支架相比,BVS与第1年和第3年间的靶病变失败和器械血栓形成率升高相关。

EuroIntervention:肥胖悖论——BMI的适度增加与PCI后患者生存率的改善相关

本研究旨在评估接受经皮血管重建术的冠状动脉疾病患者的体重指数(BMI)与结局之间的关系。

JAHA:经导管主动脉瓣植入心肌血运重建的生理vs.血管造影引导

在这项观察性研究中,FFR引导与经导管主动脉瓣植入患者较好的预后相关。

Front Bioeng Biotechnol:新型植入支架可更好的防止血栓形成和支架内再狭窄

植入支架是治疗冠状动脉疾病最有效、最微创的技术,但支架血栓形成(ST)和支架内再狭窄(IRS)的风险阻碍了愈合过程。市场上的支架种类繁多,但以临时性的设计图案为主。目前仍需要一种系统的设计方法,以提高

JAMA Cardiol:银屑病中主动脉血管炎症与冠脉斑块特征的关联

主动脉VI与广泛的CAD指标相关,提示了主动脉VI可能是早期CAD的替代指标。

Baidu
map
Baidu
map
Baidu
map